Anixa Biosciences Inc 10-Q

Item 1. Financial Statements. ANIXA BIOSCIENCES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS July 31, 2021 October 31, 2020 (Unaudited) ASSETS Current assets: Cash and cash equivalents $ 27,222,190 $ 6,417,061 Short-term investments 9,399,784 2,640,000 Prepaid expenses and other current assets 430,006 311,563 Total current assets 37,051,980 9,368,624 Operating lease right-of-use asset 10,411 54,340 Other assets - 30,000 Total assets $ 37,062,391 $ 9,452,964 LIABILITIES AND EQUITY Current liabilities: Accounts payable $ 207,733 $ 232,368 Accrued expenses 989,724 901,025 Operating lease liability 10,567 55,198 Total current liabilities 1,208,024 1,188,591 Commitments and contingencies (Note 10) Equity: Shareholders’ equity: Preferred stock, par value $ 100 per share; 19,860 shares authorized; no shares issued or outstanding - - Series A convertible preferred stock, par value $ 100 per share; 140 shares authorized; no shares issued or outstanding - - Common stock, par value $ .01 per share; 100,000,000 shares authorized; 29,949,905 and 24,248,695 shares issued and outstanding, respectively 299,499 242,486 Additional paid-in capital 236,944,345 200,354,488 Accumulated deficit ( 200,776,749 ) ( 191,835,618 ) Total shareholders’ equity 36,467,095 8,761,356 Noncontrolling interest (Note 1) ( 612,728 ) ( 496,983 ) Total equity 35,854,367 8,264,373 Total liabilities and equity $ 37,062,391 $ 9,452,964 The accompanying notes are an integral part of these condensed consolidated financial statements. 1 ANIXA BIOSCIENCES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) 2021 2020 2021 2020 For the Three Months Ended For the Nine Months Ended July 31, July 31, 2021 2020 2021 2020 Revenue $ - $ - $ 512,500 $ - Operating costs and expenses: Inventor royalties, contingent legal fees, litigation and licensing expenses - - 385,002 - Research and development expenses (including non-cash share-based compensation expenses of $ 1,687,754 , $ 394,842 , $ 2,425,136 and $ 1,250,497 , respectively) 2,166,622 1,254,131 4,016,449 3,973,509 General and administrative expenses (including non-cash share-based compensation expenses of $ 1,499,572 , $ 646,957 , $ 2,799,561 and $ 1,922,722 , respectively) 2,221,614 1,181,838 5,169,698 3,762,466 Total operating costs and expenses 4,388,236 2,435,969 9,571,149 7,735,975 Loss from operations ( 4,388,236 ) ( 2,435,969 ) ( 9,058,649 ) ( 7,735,975 ) Other expense - ( 148,084 ) - ( 148,084 ) Interest income 626 7,266 1,773 32,707 Net loss ( 4,387,610 ) ( 2,576,787 ) ( 9,056,876 ) ( 7,851,352 ) Less: Net loss attributable to noncontrolling interest ( 53,621 ) ( 15,103 ) ( 115,745 ) ( 57,032 ) Net loss attributable to common shareholders $ ( 4,333,989 ) $ ( 2,561,684 ) $ ( 8,941,131 ) $ ( 7,794,320 ) Net loss per common share attributable to common shareholders: Net loss per common share attributable to common shareholders: Basic and diluted $ ( 0.14 ) $ ( 0.11 ) $ ( 0.32 ) $ ( 0.36 ) Weighted average common shares outstanding: Weighted average common shares outstanding: Basic and diluted 30,455,340 23,165,066 28,090,163 21,678,608 The accompanying notes are an integral part of these condensed consolidated financial statements. 2 ANIXA BIOSCIENCES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY (UNAUDITED ) FOR THE THREE MONTHS ENDED JULY 31, 2021 Shares Par Value Paid-in Capital Accumulated Deficit Shareholders’ Equity controlling Interest Total Equity Common Stock Additional Total Non- Shares Par Value Paid-in Capital Accumulated Deficit Shareholders’ Equity controlling Interest Total Equity Balance, April 30, 2021 31,449,905 $ 314,499 $ 233,742,019 $ ( 196,442,760 ) $ 37,613,758 $ ( 559,107 ) $ 37,054,651 Stock option compensation to employees and directors - - 3,047,877 - 3,047,877 - 3,047,877 Stock options issued to consultants Common stock issued upon exercise of stock options Common stock issued upon exercise of stock options, shares Common stock issued in at-the-market offering, net of offering expenses Common stock issued in at-the-market offering, net of offering expenses, shares Common stock issued pursuant to employee stock purchase plan Common stock issued pursuant to employee stock purchase plan, shares Common stock issued in a public offering, net of offering expenses Common stock issued in a public offering, net of offering expenses, shares Expired restricted stock award to employee ( 1,500,000 ) ( 15,000 ) 15,000 - - - Stock options and warrants issued to consultants - - 139,449 - 139,449 - 139,449 Net loss - - - ( 4,333,989 ) ( 4,333,989 ) ( 53,621 ) ( 4,387,610 ) Balance, July 31, 2021 29,949,905 $ 299,499 $ 236,944,345 $ ( 200,776,749 ) $ 36,467,095 $ ( 612,728 ) $ 35,854,367 FOR THE THREE MONTHS ENDED July 31, 2020 Common Stock Additional Total Non- Shares Par Value Paid-in Capital Accumulated Deficit Shareholders’ Equity controlling Interest Total Equity Balance, April 30, 2020 21,479,335 $ 214,793 $ 192,122,260 $ ( 187,049,899 ) $ 5,287,154 $ ( 464,904 ) $ 4,822,250 Stock option compensation to employees and directors - - 997,094 - 997,094 - 997,094 Stock options issued to consultants - - 44,705 - 44,705 - 44,705 Common stock issued upon exercise of stock options 7,200 72 18,468 - 18,540 - 18,540 Common stock issued in at-the-market offering, net of offering expenses of $ 155,776 2,167,219 21,672 4,810,533 - 4,832,205 - 4,832,205 Net loss - - - ( 2,561,684 ) ( 2,561,684 ) ( 15,103 ) ( 2,576,787 ) Balance, July 31, 2020 23,653,754 $ 236,537 $ 197,993,060 $ ( 189,611,583 ) $ 8,618,014 $ ( 480,007 ) $ 8,138,007 The accompanying notes are an integral part of these condensed consolidated financial statements. 3 ANIXA BIOSCIENCES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY (UNAUDITED ) FOR THE NINE MONTHS ENDED JULY 31, 2021 Common Stock Additional Total Non- Shares Par Value Paid-in Capital Accumulated Deficit Shareholders’ Equity controlling Interest Total Equity Balance, October 31, 2020 24,248,695 $ 242,486 $ 200,354,488 $ ( 191,835,618 ) $ 8,761,356 $ ( 496,983 ) $ 8,264,373 Stock option compensation to employees and directors - - 4,803,515 - 4,803,515 - 4,803,515 Expired restricted stock award to employee ( 1,500,000 ) ( 15,000 ) 15,000 - - - Stock options and warrants issued to consultants - - 421,182 - 421,182 - 421,182 Common stock issued upon exercise of stock options 107,451 1,075 292,529 - 293,604 - 293,604 Common stock issued pursuant to employee stock purchase plan 1,634 16 2,984 - 3,000 - 3,000 Common stock issued in a public offering, net of offering expenses of $ 2,208,150 4,285,715 42,858 20,248,996 - 20,291,854 - 20,291,854 Common stock issued in at-the-market offering, net of offering expenses of $ 340,775 2,806,410 28,064 10,805,651 - 10,833,715 - 10,833,715 Net loss - - - ( 8,941,131 ) ( 8,941,131 ) ( 115,745 ) ( 9,056,876 ) Balance, July 31, 2021 29,949,905 $ 299,499 $ 236,944,345 $ ( 200,776,749 ) $ 36,467,095 $ ( 612,728 ) $ 35,854,367 FOR THE NINE MONTHS ENDED JULY 31, 2020 Common Stock Additional Total Non- Shares Par Value Paid-in Capital Accumulated Deficit Shareholders’ Equity controlling Interest Total Equity Balance, October 31, 2019 20,331,754 $ 203,317 $ 186,849,299 $ ( 181,817,263 ) $ 5,235,353 $ ( 422,975 ) $ 4,812,378 Stock option compensation to employees and directors - - 3,016,305 - 3,016,305 - 3,016,305 Stock options issued to consultants - - 156,914 - 156,914 - 156,914 Common stock issued upon exercise of stock options 51,100 511 121,759 - 122,270 - 122,270 Common stock issued pursuant to employee stock purchase plan 9,618 96 15,356 - 15,452 - 15,452 Common stock issued in at-the-market offering, net of offering expenses of $ 314,072 3,261,282 32,613 7,833,427 - 7,866,040 - 7,866,040 Common stock issued in at-the-market offering, net of offering expenses 3,261,282 32,613 7,833,427 - 7,866,040 - 7,866,040 Net loss - - - ( 7,794,320 ) ( 7,794,320 ) ( 57,032 ) ( 7,851,352 ) Balance, July 31, 2020 23,653,754 $ 236,537 $ 197,993,060 $ ( 189,611,583 ) $ 8,618,014 $ ( 480,007 ) $ 8,138,007 The accompanying notes are an integral part of these condensed consolidated financial statements. 4 ANIXA BIOSCIENCES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) 2021 2020 For the nine months ended July 31, 2021 2020 Cash flows from operating activities: Reconciliation of net loss to net cash used in operating activities: Net loss $ ( 9,056,876 ) $ ( 7,851,352 ) Stock option compensation to employees and directors 4,803,515 3,016,305 Stock options and warrants issued to consultants 421,182 156,914 Depreciation of property and equipment - 38,276 Loss on disposal of property and equipment - 148,084 Gain on sale of equipment ( 5,447 ) - Amortization of operating lease right-of-use asset 43,929 38,317 Change in operating assets and liabilities: Receivables - 60,577 Prepaid expenses and other current assets ( 118,443 ) ( 4,870 ) Accounts payable ( 24,635 ) ( 246,522 ) Accrued expenses 88,699 ( 79,781 ) Operating lease liability ( 44,631 ) ( 37,537 ) Net cash used in operating activities ( 3,892,707 ) ( 4,761,589 ) Cash flows from investing activities: Disbursements to acquire short-term investments ( 10,399,784 ) ( 5,510,000 ) Proceeds from maturities of short-term investments 3,640,000 4,720,000 Purchase of property and equipment - ( 15,791 ) Proceeds from sale of equipment 35,447 - Net cash used in investing activities ( 6,724,337 ) ( 805,791 ) Cash flows from financing activities: Gross proceeds from sale of common stock in a public offering 22,500,004 - Expenses of the public offering ( 2,208,150 ) - Gross proceeds from sale of common stock in an at-the-market offering 11,174,490 8,180,112 Expenses of the at-the-market offering ( 340,775 ) ( 314,072 ) Proceeds from sale of common stock pursuant to employee stock purchase plan 3,000 15,452 Proceeds from exercise of stock options 293,604 122,270 Net cash provided by financing activities 31,422,173 8,003,762 Net increase in cash and cash equivalents 20,805,129 2,436,382 Cash and cash equivalents at beginning of period 6,417,061 3,491,625 Cash and cash equivalents at end of period $ 27,222,190 $ 5,928,007 Supplemental cash flow information: Cash proceeds from interest income $ 1,675 $ 38,930 Supplemental disclosure of non-cash financing activity: Fair value of warrants issued in connection with the public offering $ 1,040,700 $ - The accompanying notes are an integral part of these condensed consolidated financial statements. 5 ANIXA BIOSCIENCES, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) 1. BUSINESS AND FUNDING Description of Business As used herein, “we,” “us,” “our,” the “Company” or “Anixa” means Anixa Biosciences, Inc. and its consolidated subsidiaries. Our primary operations involve developing therapies and vaccines that are focused on critical unmet needs in oncology and infectious disease. Our therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (“CAR-T”) technology, initially focused on treating ovarian cancer, and discovery and ultimately development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Our vaccine programs include the development of a vaccine against breast cancer, specifically triple negative breast cancer (“TNBC”), the most lethal form of the disease, and a vaccine against ovarian cancer. Our subsidiary, Certainty Therapeutics, Inc. (“Certainty”), is developing immuno-therapy drugs against cancer. Certainty holds an exclusive worldwide, royalty-bearing license to use certain intellectual property owned or controlled by The Wistar Institute (“Wistar”) relating to Wistar’s CAR-T technology. We have initially focused on the development of a treatment for ovarian cancer, but we may also pursue applications of the technology for the development of treatments for additional solid tumors. The license agreement requires Certainty to make certain cash and equity payments to Wistar upon achievement of specific development milestones. With respect to Certainty’s equity obligations to Wistar, Certainty issued to Wistar shares of its common stock equal to five percent ( 5 %) of the common stock of Certainty. Certainty, in collaboration with the H. Lee Moffitt Cancer Center and Research Institute, Inc. (“Moffitt”), is advancing toward human clinical testing its CAR-T technology for treating ovarian cancer. We submitted an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) in March 2021. In April 2021, the FDA informed us that they needed additional information before allowing us to proceed with the clinical trial. In May 2021, the FDA provided us with the details of their information request. Through an iterative process with the FDA, we responded to their information requests and in August 2021, we received authorization from the FDA to commence enrollment and treatment of patients in a Phase 1 clinical trial. We are performing the activities necessary to prepare for treatment of patients in the Phase 1 clinical trial, and we anticipate treating the first enrolled patient in early 2022. In April 2020, we entered into a collaboration with OntoChem GmbH (“OntoChem”), to discover and ultimately develop anti-viral drug candidates against COVID-19. Through this collaboration, we utilized advanced computational methods, machine learning, and molecular modeling techniques to perform in silico screening of over 1.2 billion compounds in chemical libraries (including publicly available compounds and OntoChem’s proprietary libraries) to evaluate if any of these compounds could disrupt one of two key enzymes of SARS-CoV-2, the virus that causes the disease COVID-19. The screening process resulted in the identification of multiple compounds that could potentially disrupt critical enzymes of the virus. Several of these compounds were synthesized and tested in in vitro biological assays. Upon completion of these biological assays, we identified two of the most promising compounds and tested them in animal models. In these animal studies, the two compounds were compared to Remdesivir, which is the only anti-viral drug authorized by the FDA for COVID-19. The data showed that administration of the drugs to infected hamsters did not cause any noticeable adverse effects, and monitoring of weight and general animal behavior demonstrated comparable efficacy of both compounds as well as Remdesivir. Based on this promising data in the animal study, we proceeded to the next stage of drug development and selected one of the compounds around which we are currently performing combinatorial synthetic medicinal chemistry to evaluate whether we can increase potency and optimize pharmacokinetics. In addition, we have added chemical structures which we feel, based on our data and recently published data, could be potent anti-virals. 6 In May 2021, after completion of the aforementioned animal studies, OntoChem assigned its rights and obligations related to this collaboration to MolGenie GmbH (“MolGenie”), a company spun-out from OntoChem focused on drug discovery and development. In August 2021, in an attempt to evaluate whether our compounds might be effective against the Delta variant of SARS-CoV-2, we undertook an analysis of certain enzyme mutations in the Delta variant. We note that the Delta variant is characterized by mutations in the spike protein of the virus. Corresponding to the mutations in the spike protein, we found some of the Delta variants exhibited a mutation in the enzyme that is our target. Sequence analysis of several Delta variant samples demonstrated that the resultant enzyme mutation indicates that our novel compounds could be stronger inhibitors of the Delta variant that the original version of the virus. We hold an exclusive worldwide, royalty-bearing license to use certain intellectual property owned or controlled by The Cleveland Clinic Foundation (“Cleveland Clinic”) relating to certain breast cancer vaccine technology developed at Cleveland Clinic. We are working in collaboration with Cleveland Clinic to develop a method to vaccinate women against contracting breast cancer, focused specifically on TNBC. A specific protein, alpha-lactalbumin, has been identified that is only expressed during lactation in a healthy woman’s mammary tissue. This protein disappears when the woman is no longer lactating, but reappears in many forms of breast cancer, especially TNBC. Studies have shown that vaccinating against this protein prevents breast cancer in mice. In December 2020, we received authorization from the FDA to commence enrollment and treatment of patients in a Phase 1a clinical trial. We are performing the activities necessary to prepare for treatment of patients in the Phase 1a clinical trial, and we anticipate treating the first enrolled patient in September 2021. In November 2020, we executed a license agreement with Cleveland Clinic pursuant to which the Company was granted an exclusive worldwide, royalty-bearing license to use certain intellectual property owned or controlled by Cleveland Clinic relating to certain ovarian cancer vaccine technology. This technology pertains to the use of vaccines for the treatment or prevention of ovarian cancers which express the anti-Mullerian hormone receptor II protein containing an extracellular domain (“AMHR2-ED”). In healthy tissue, this protein regulates growth and development of egg-containing follicles in the ovary. While expression of AMHR2-ED naturally and markedly declines after menopause, this protein is expressed at high levels in the ovaries of postmenopausal women with ovarian cancer. Researchers at Cleveland Clinic believe that a vaccine targeting AMHR2-ED could prevent the occurrence of ovarian cancer. We entered into a joint development agreement with Cleveland Clinic, to advance this vaccine technology toward human clinical testing. In May 2021, Cleveland Clinic was granted an award for our ovarian cancer vaccine technology by the National Cancer Institute’s (“NCI”) PREVENT program. The NCI is a part of the National Institutes of Health. The PREVENT program is a peer-reviewed agent development program designed to support preclinical development of innovative interventions and biomarkers for cancer prevention and interception towards clinical trials. The scientific and financial resources of the PREVENT program will be used for our ovarian cancer vaccine technology to perform virtually all pre-clinical research and development, manufacturing and IND-enabling studies. This work will be performed at NCI facilities, by NCI scientific staff and with NCI financial resources and will require no material financial expenditures by the Company, nor the transfer of any rights to the Company’s assets. Over the next several quarters, we expect the development of our breast and ovarian cancer vaccines, our COVID-19 therapeutic program and Certainty’s CAR-T technology to be the primary focus of the Company. As part of our legacy operations, the Company remains engaged in limited patent licensing activities regarding the Cchek™ liquid biopsy platform (operations for which were suspended in July 2020), as well as in the area of encrypted audio/video conference calling. We do not expect these activities to be a significant part of the Company’s ongoing operations, nor do we expect these activities to require material financial resources or attention of senior management. 7 Over the past several years, our revenue, if any, was derived from technology licensing and the sale of patented technologies, including revenue from the settlement of litigation. We have not generated any revenue to date from our therapeutics or vaccine programs. In addition, while we pursue our therapeutics and vaccine programs, we may also make investments in and form new companies to develop additional emerging technologies. We do not expect to begin generating revenue with respect to any of our current therapy or vaccine programs in the near term. We hope to achieve a profitable outcome by eventually licensing our technologies to large pharmaceutical companies that have the resources and infrastructure in place to manufacture, market and sell our technologies as therapeutics or vaccines. The eventual licensing of any of our technologies may take several years, if it is to occur at all, and may depend on positive results from human clinical trials. Funding and Management’s Plans Based on currently available information as of September 1, 2021, we believe that our existing cash, cash equivalents, short-term investments and expected cash flows will be sufficient to fund our activities for at least the next twelve months. We have implemented a business model that conserves funds by collaborating with third parties to develop our technologies. However, our projections of future cash needs and cash flows may differ from actual results. If current cash on hand, cash equivalents, short-term investments and cash that may be generated from our business operations are insufficient to continue to operate our business, or if we elect to invest in or acquire a company or companies or new technology or technologies that are synergistic with or complementary to our technologies, we may be required to obtain more working capital. During the nine months ended July 31, 2021, we raised approximately $ 20,292,000 , net of expenses, through a public offering in which we sold an aggregate of 4,285,715 shares of common stock and approximately $ 10,834,000 , net of expenses, through our at-the-market equity program in which we sold an aggregate of 2,806,410 shares of common stock. Our at-the-market equity program was terminated on June 16, 2021. We may seek to obtain working capital during our fiscal year 2021 or thereafter through sales of our equity securities or through bank credit facilities or public or private debt from various financial institutions where possible. We cannot be certain that additional funding will be available on acceptable terms, or at all. If we do identify sources for additional funding, the sale of additional equity securities or convertible debt will result in dilution to our stockholders. We can give no assurance that we will generate sufficient cash flows in the future to satisfy our liquidity requirements or sustain future operations, or that other sources of funding, such as sales of equity or debt, would be available or would be approved by our security holders, if needed, on favorable terms or at all. If we fail to obtain additional working capital as and when needed, such failure could have a material adverse impact on our business, results of operations and financial condition. Furthermore, such lack of funds may inhibit our ability to respond to competitive pressures or unanticipated capital needs, or may force us to reduce operating expenses, which would significantly harm the business and development of operations. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, certain information and disclosures required by generally accepted accounting principles in annual financial statements have been omitted or condensed. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related disclosures included in our Annual Report on Form 10-K for the year ended October 31, 2020. The accompanying October 31, 2020 condensed consolidated balance sheet data was derived from the audited financial statements but does not include all disclosures required by US GAAP. The condensed consolidated financial statements include all adjustments of a normal recurring nature which, in the opinion of management, are necessary for a fair statement of our financial position as of July 31, 2021, and results of operations and cash flows for the interim periods represented. The results of operations for the nine months ended July 31, 2021 are not necessarily indicative of the results to be expected for the entire year. 8 Noncontrolling Interest Noncontrolling interest represents Wistar’s equity ownership in Certainty and is presented as a component of equity. The following table sets forth the changes in noncontrolling interest for the nine months ended July 31, 2021: SCHEDULE OF CHANGES IN NONCONTROLLING INTEREST Balance, October 31, 2020 $ ( 496,983 ) Net loss attributable to noncontrolling interest ( 115,745 ) Balance, July 31, 2021 $ ( 612,728 ) Revenue Recognition Our revenue has been derived solely from technology licensing and the sale of patented technologies. Revenue is recognized upon transfer of control of intellectual property rights and satisfaction of other contractual performance obligations to licensees in an amount that reflects the consideration we expect to receive. We follow the accounting guidance of Accounting Standards Codification 606 (“ASC 606”), Revenue from Contracts with Customers. In accordance with ASC 606 we are required to make certain judgments and estimates in connection with the accounting for revenue. Such judgments and estimates may include determining the existence of a contract and identifying each party’s rights and obligations to transfer goods and services, identifying the performance obligations in the contract, determining the transaction price and allocating the transaction price to separate performance obligations, estimating the timing of satisfaction of performance obligations, determining whether a promise to grant a license is distinct from other promised goods or services and evaluating whether a license transfers to a customer at a point in time or over time. Our revenue arrangements provide for the payment, within 30 days of execution of the agreement, of contractually determined, one-time, paid-up license fees in settlement of litigation and in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company. These arrangements typically include some combination of the following: (i) the grant of a non-exclusive, retroactive and future license to manufacture and/or sell products covered by patented technologies owned or controlled by the Company, (ii) a covenant-not-to-sue, (iii) the release of the licensee from certain claims, and (iv) the dismissal of any pending litigation. In such instances, the intellectual property rights granted have been perpetual in nature, extending until the expiration of the related patents. Pursuant to the terms of these agreements, we have no further obligations with respect to the granted intellectual property rights, including no obligation to maintain or upgrade the technology, or provide future support or services. Licensees obtained control of the intellectual property rights they have acquired upon execution of the agreement. Accordingly, the performance obligations from these agreements were satisfied and 100% of the revenue was recognized upon the execution of the agreements. Cost of Revenues Cost of revenues include the costs and expenses incurred in connection with our patent licensing and enforcement activities, including inventor royalties paid to original patent owners, contingent legal fees paid to external counsel, other patent-related legal expenses paid to external counsel and licensing and enforcement related research, consulting and other expenses paid to third-parties. These costs are included under the caption “Operating costs and expenses” in the accompanying condensed consolidated statements of operations. 9 Research and Development Expenses Research and development expenses, consisting primarily of employee compensation, payments to third parties for research and development activities and other direct costs associated with developing immuno-therapy drugs against cancer, preventative cancer vaccines and anti-viral drug candidates for COVID-19, are expensed in the accompanying condensed consolidated financial statements in the period incurred. 2. PUBLIC OFFERING On March 25, 2021, the Company completed a public offering in which we sold an aggregate of 4,285,715 shares of its common stock, which represented 15.8 % of the Company’s outstanding shares at the time of the offering, at a public offering price of $ 5.25 per share. The Company realized net proceeds of approximately $ 20,292,000 from the public offering, after deducting underwriting discounts and deal expenses. In connection with the public offering, the Company issued to certain designees of the underwriter, as compensation, warrants expiring on March 22, 2026 , to purchase 300,000 shares of common stock at $ 6.5625 per share. 3. STOCK BASED COMPENSATION The Company maintains stock equity incentive plans under which the Company grants incentive stock options, non-qualified stock options, stock appreciation rights, stock awards, performance awards, or stock units to employees, directors and consultants. Stock Option Compensation Expense The compensation cost for service-based stock options granted to employees and directors is measured at the grant date, based on the fair value of the award using the Black-Scholes pricing model, and is expensed on a straight-line basis over the requisite service period (the vesting period of the stock option) which is one to four years . We recorded stock-based compensation expense related to service-based stock options granted to employees and directors of approximately $ 1,066,000 and $ 997,000 during the three months ended July 31, 2021 and 2020, respectively, and approximately $ 2,822,000 and $ 3,016,000 during the nine months ended July 31, 2021 and 2020, respectively. For stock options granted to employees and directors that vest based on market conditions, such as the trading price of the Company’s common stock exceeding certain price targets, we use a Monte Carlo Simulation in estimating the fair value at grant date and recognize compensation cost over the implied service period (median time to vest). On May 8, 2018, we issued market condition options to purchase 1,500,000 shares of common stock, to our Chairman, President and Chief Executive Officer, vesting at target trading prices of $ 5.00 to $ 8.00 per share before May 31, 2021 , with implied service periods of three to seven months. In October 2018, the first tranche of 500,000 shares of market condition options became exercisable upon achieving an average closing price above $ 5.00 per share for twenty consecutive trading days. The remaining tranches did not vest as of May 31, 2021 and expired. On June 1, 2021, our Chairman, President and Chief Executive Officer and our Chief Operating Officer and Chief Financial Officer were awarded options for 2,000,000 shares and 100,000 shares of common stock, respectively, that vest in four equal installments upon the Company’s share price achieving targets ranging from $ 5.00 to $ 8.00 per share, with implied service periods of three to fifteen months. The assumptions used in the Monte Carlo Simulation for the June 1, 2021 grants were stock price on date of grant of $ 4.02 , contract term of 10 years, expected volatility of 75 % and risk-free interest rate of 1.62 %. We recorded stock-based compensation expense related to market condition stock options of approximately $ 1,981,000 for both the three and nine month periods ended July 31, 2021. We did not record any market condition stock-based compensation expense for these grants during the three and nine month periods ended July 31, 2020. As of July 31, 2021, the unrecognized compensation cost related to market condition stock options was approximately $ 4,528,000 which will be recognized over future periods through the fourth quarter of fiscal 2022. 10 The compensation cost for service-based stock options granted to consultants is measured at the grant date, based on the fair value of the award using the Black-Scholes pricing model, and is expensed on a straight-line basis over the requisite service period (the vesting period of the stock option) which is one to three years. We recorded stock-based consulting expense related to stock options granted to consultants of approximately $ 139,000 and $ 45,000 during the three months ended July 31, 2021 and 2020, respectively, and approximately $ 326,000 and $ 157,000 during the nine months ended July 31, 2021 and 2020, respectively. Stock Option Plans During the nine months ended July 31, 2021, we had two stock option plans: the Anixa Biosciences, Inc. 2010 Share Incentive Plan (the “2010 Share Plan”) and the Anixa Biosciences, Inc. 2018 Share Incentive Plan (the “2018 Share Plan”), which were adopted by our Board of Directors on July 14, 2010 and January 25, 2018, respectively. The 2018 Share Plan was approved by our shareholders on March 29, 2018. Further, we had an additional stock option plan: the Anixa Biosciences, Inc. 2003 Share Incentive Plan (the “2003 Share Plan”), under which all outstanding options expired during the nine months ended July 31, 2020. Stock Option Activity During the three months ended July 31, 2021 and 2020, we granted options to purchase 2,990,000 shares and - 0 - shares of common stock, respectively, and during the nine months ended July 31, 2021 and 2020, we granted options to purchase 4,370,000 shares and 800,000 shares of common stock, respectively, to employees and consultants, with exercise prices ranging from $ 2.83 to $ 5.30 per share, pursuant to the 2018 Share Plan. During the three months ended July 31, 2021 and 2020, stock options to purchase - 0 - shares and 7,200 shares of common stock, respectively, were exercised with aggregate proceeds of approximately $- 0 - and $ 19,000 , respectively. During the nine months ended July 31, 2021 and 2020, stock options to purchase 107,451 shares, net of 7,937 shares withheld on a cashless exercise, and 51,100 shares of common stock, respectively, were exercised with aggregate proceeds of approximately $ 294,000 and $ 122,000 , respectively. 2003 Share Plan The 2003 Share Plan provided for the grant of nonqualified stock options, stock appreciation rights, stock awards, performance awards and stock units to employees, directors and consultants. In accordance with the provisions of the 2003 Share Plan, the plan terminated with respect to the ability to grant future awards on April 21, 2013. Information regarding the 2003 Plan for the nine months ended July 31, 2020 is as follows: SCHEDULE OF OPTION ACTIVITY Shares Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Options outstanding at October 31, 2019 400 $ 17.00 Granted - $ - Exercised                  - $ - Forfeited/Expired ( 400 ) $ 17.00 Options outstanding and exercisable at July 31, 2020 - $ - 0 - $ - 0 - Options outstanding at July 31, 2020 - $ - $ - Options exercisable at July 31, 2020 - $ - $ - 11 2010 Share Plan The 2010 Share Plan provided for the grant of nonqualified stock options, stock appreciation rights, stock awards, performance awards and stock units to employees, directors and consultants. In accordance with the provisions of the 2010 Share Plan, the plan terminated with respect to the ability to grant future awards on July 14, 2020. Information regarding the 2010 Share Plan for the nine months ended July 31, 2021 is as follows: SCHEDULE OF OPTION ACTIVITY Shares Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Options outstanding at October 31, 2020 1,907,534 $ 2.82 Exercised                  ( 37,500 ) $ 2.40 Forfeited/Expired ( 10,400 ) $ 4.57 Options outstanding and exercisable at July 31, 2021 1,859,634 $ 2.82 $ 3,138,347 The following table summarizes information about stock options outstanding and exercisable under the 2010 Share Plan as of July 31, 2021: SCHEDULE OF OUTSTANDING AND EXERCISABLE Range of Exercise Prices Number Outstanding And Exercisable Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 0 $ .67 - $ 2.30 527,500 4.80 $ 1.54 $ 2.58 - $ 3.13 818,000 2.65 $ 2.80 $ 3.46 - $ 5.30 514,134 6.75 $ 4.16 Information regarding the 2010 Share Plan for the nine months ended July 31, 2020 is as follows: Shares Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Options outstanding at October 31, 2019 1,998,668 $ 2.80 Exercised ( 51,100 ) $ 2.39 Forfeited/Expired ( 20,534 ) $ 1.72 Options outstanding at July 31, 2020 1,927,034 $ 2.82 $ 731,670 Options exercisable at July 31, 2020 1,772,034 $ 2.84 $ 630,120 12 The following table summarizes information about stock options outstanding and exercisable under the 2010 Share Plan as of July 31, 2020: Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price Number Exercisable Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 0.67 - $ 2.30 549,000 5.70 $ 1.57 494,000 5.56 $ 1.64 $ 2.58 - $ 3.13 846,000 3.05 $ 2.79 846,000 3.41 $ 2.79 $ 3.46 - $ 5.75 532,034 7.45 $ 4.16 432,034 7.33 $ 4.33 2018 Share Plan The 2018 Share Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, stock awards, performance awards and stock units to employees, directors and consultants. As of July 31, 2021, the 2018 Share Plan had 1,257,937 shares available for future grants. Information regarding the 2018 Share Plan for the nine months ended July 31, 2021 is as follows: SCHEDULE OF OPTION ACTIVITY Shares Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Options outstanding at October 31, 2020 4,346,661 $ 3.69 Granted 4,370,000 $ 3.79 Exercised ( 33,888 ) $ 3.81 Forfeited/Expired ( 1,392,781 ) $ 3.70 Options outstanding at July 31, 2021 7,289,992 $ 3.74 $ 5,164,696 Options exercisable at July 31, 2021 2,914,586 $ 3.64 $ 2,328,335 The following table summarizes information about stock options outstanding and exercisable under the 2018 Share Plan as of July 31, 2021: SCHEDULE OF OUTSTANDING AND EXERCISABLE Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price Number Exercisable Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 2.09 - $ 3.70 2,975,000 7.90 $ 3.28 2,047,360 7.25 $ 3.49 $ 3.84 - $ 5.30 4,314,992 8.95 $ 4.06 867,226 7.33 $ 3.99 13 Information regarding the 2018 Share Plan for the nine months ended July, 2020 is as follows: SCHEDULE OF OPTION ACTIVITY Shares Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Options outstanding at October 31, 2019 3,935,000 $ 3.74 Granted 800,000 $ 3.85 Forfeited/Expired ( 258,376 ) $ 3.86 Options outstanding at July 31, 2020 4,476,624 $ 3.76 $ - 0 - Options exercisable at July 31, 2020 2,403,014 $ 3.76 $ - 0 - The following table summarizes information about stock options outstanding and exercisable under the 2018 Share Plan as of July 31, 2020: Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price Number Exercisable Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 3.70 3,100,000 7.78 $ 3.70 1,700,000 7.78 $ 3.70 $ 3.84 - $ 4.61 1,376,624 7.55 $ 3.89 703,014 6.15 $ 3.90 Non-Plan Options In addition to options granted under stock option plans, during the years ended October 31, 2012 and 2013, the Board of Directors approved the grant of stock options to certain employees and directors (the “Non-Plan Options”). Information regarding Non-Plan Options for the nine months ended July 31, 2021 is as follows: SCHEDULE OF OPTION ACTIVITY Shares Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Options outstanding at October 31, 2020 1,698,000 $ 2.58 Exercised ( 44,000 ) $ 2.58 Options outstanding and exercisable at July 31, 2021 1,654,000 $ 2.58 $ 3,051,630 The following table summarizes information about Non-Plan Options outstanding and exercisable as of July 31, 2021: SCHEDULE OF OUTSTANDING AND EXERCISABLE Range of Exercise Prices Number Outstanding and Exercisable Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 2.58 1,654,000 1.06 $ 2.58 14 Information regarding Non-Plan Options for the nine months ended July 31, 2020 is as follows: Shares Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Options outstanding at October 31, 2019 1,698,000 $ 2.58 Options outstanding and exercisable at July 31, 2020 1,698,000 $ 2.58 $ 348,000 The following table summarizes information about Non-Plan Options outstanding and exercisable as of July 31, 2020: Range of Exercise Prices Number Outstanding and Exercisable Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 2.58 1,698,000 2.00 $ 2.58 Stock Awards On May 8, 2018, a restricted stock award of 1,500,000 shares of common stock was granted under the 2018 Share Plan to our Chairman, President and Chief Executive Officer. The restricted stock award was to vest in its entirety upon achievement of a target trading price of $ 11.00 per share of the Company’s common stock before May 31, 2021 . The restricted stock award did not vest as of May 31, 2021 and expired. For restricted stock awards vesting upon achievement of a price target of our common stock we use a Monte Carlo Simulation in estimating the fair value at grant date and recognize compensation cost over the implied service period (median time to vest). We did not record any compensation expense related to the restricted stock award during the nine months ended July 31, 2021 and 2020. Employee Stock Purchase Plan The Company maintains the Anixa Biosciences, Inc. Employee Stock Purchase Plan which permits eligible employees to purchase shares at not less than 85 % of the market value of the Company’s common stock on the offering date or the purchase date of the applicable offering period, whichever is lower. The plan was adopted by our Board of Directors on August 13, 2018 and approved by our shareholders on September 27, 2018. During the nine months ended July 31, 2021 and 2020, employees purchased 1,634 and 9,618 shares, respectively, with aggregate proceeds of approximately $ 3,000 and $ 15,000 , respectively. Warrants On October 30, 2020 we issued a warrant, expiring on October 30, 2025 , to purchase 60,000 shares of common stock at $ 2.06 per share, vesting over five months, to a consultant for investor relations services. We recorded consulting expense of approximately $ -0- and $ 96,000 , respectively, during the three and nine months ended July 31, 2021, based on the fair value of the warrant on the date of grant recognized on a straight-line basis over the vesting period. We did no t record any consulting expense related to warrants during the three and nine months ended July 31, 2020. As discussed in Note 2, in connection with the March 25, 2021 public offering we issued to certain designees of the underwriter, as compensation, warrants to purchase 300,000 shares of common stock at $ 6.5625 per share, expiring on March 22, 2026 . No warrants were issued during the nine month period ended July 31, 2020. 15 As of July 31, 2021, we also had warrants outstanding to purchase 500,000 shares of common stock at $ 5.03 per share, issued during fiscal year 2017 and expiring on November 30, 2021 . 4. FAIR VALUE MEASUREMENTS US GAAP defines fair value and establishes a framework for measuring fair value. We have categorized our financial assets and liabilities, based on the priority of the inputs to the valuation technique, into a three-level fair value hierarchy as set forth below. If the inputs used to measure the financial instruments fall within different levels of the hierarchy, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument. Financial assets and liabilities recorded in the accompanying condensed consolidated balance sheets are categorized based on the inputs to the valuation techniques as follows: Level 1 - Financial assets and liabilities whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market which we have the ability to access at the measurement date. Level 2 - Financial assets and liabilities whose values are based on quoted market prices in markets where trading occurs infrequently or whose values are based on quoted prices of instruments with similar attributes in active markets. Level 3 – Financial assets and liabilities whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management’s own assumptions about the assumptions a market participant would use in pricing the asset and liabilities. The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of July 31, 2021: SCHEDULE OF FAIR VALUE MEASUREMENTS Level 1 Level 2 Level 3 Total Money market funds: Cash and cash equivalents $ 26,807,696 $ - $ - $ 26,807,696 Certificates of deposit: Cash and cash equivalents 250,000 - - 250,000 Short-term investments - 1,000,000 - 1,000,000 Treasury bills and bonds: Short-term investments - 8,399,784 - 8,399,784 Total financial assets $ 27,057,696 $ 9,399,784 $ - $ 36,457,480 The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of October 31, 2020: Level 1 Level 2 Level 3 Total Money market funds: Cash and cash equivalents $ 3,902,292 $ - $ - $ 3,902,292 Certificates of deposit: Cash and cash equivalents 2,250,000 - - 2,250,000 Short-term investments - 2,640,000 - 2,640,000 Total financial assets $ 6,152,292 $ 2,640,000 $ - $ 8,792,292 16 Our non-financial assets that are measured on a non-recurring basis include our other assets which are measured using fair value techniques whenever events or changes in circumstances indicate a condition of impairment exists. The estimated fair value of prepaid expenses and other current assets, accounts payable and accrued expenses approximates their individual carrying amounts due to the short-term nature of these measurements. Cash and cash equivalents are stated at carrying value which approximates fair value. 5. ACCRUED EXPENSES Accrued expenses consist of the following as of: SCHEDULE OF ACCRUED EXPENSES July 31, 2021 October 31, 2020 Payroll and related expenses $ 392,376 $ 415,331 Accrued royalty and contingent legal fees 577,190 449,691 Accrued collaborative research and license expense - 30,000 Accrued other 20,158 6,003 Accrued expenses $ 989,724 $ 901,025 6. NET LOSS PER SHARE OF COMMON STOCK Basic net loss per common share (“Basic EPS”) is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted net loss per common share (“Diluted EPS”) is computed by dividing net loss by the weighted average number of common shares and dilutive common share equivalents and convertible securities then outstanding. Diluted EPS for all periods presented is the same as Basic EPS, as the inclusion of the effect of common share equivalents then outstanding would be anti-dilutive. For this reason, excluded from the calculation of Diluted EPS for the nine months ended July 31, 2021 and 2020, were stock options to purchase 10,303,626 and 8,101,658 shares, respectively, and warrants to purchase 860,000 and 500,000 shares, respectively. 7. EFFECT OF RECENTLY ADOPTED AND ISSUED PRONOUNCEMENTS In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2016-02 (“ASU 2016-02”) Accounting Standards Codification Topic 842, Leases (“ASC 842”), which supersedes Topic 840, Leases, and which requires lessees to recognize most leases on the balance sheet. The new lease standard does not substantially change lessor accounting. For public companies, the standard was effective for the first interim reporting period within annual periods beginning after December 15, 2018, although early adoption was permitted. Lessees and lessors were required to apply the new standard at the beginning of the earliest period presented in the financial statements in which they first apply the new guidance. In July 2018, FASB issued ASU 2018-11, Leases, which provides an additional transition option for an entity to apply the provisions of ASC 842 by recognizing a cumulative effect adjustment at the effective date of adoption without adjusting the prior comparative periods presented. The requirements of this standard include a significant increase in required disclosures. The Company adopted ASU 2016-02 on November 1, 2019. The adoption of this standard did not have a material impact on our condensed consolidated financial statements. See Note 9 regarding the accounting and disclosures related to our office lease. In January 2020, the FASB issued Accounting Standards Update 2020-01 (“ASU 2020-01”) Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815). The amendments in ASU 2020-01 clarify certain interactions between the guidance to account for certain equity securities under Topic 321, the guidance to account for investments under the equity method of accounting in Topic 323, and the guidance in Topic 815, which could change how an entity accounts for an equity security under the measurement alternative or a forward contract or purchased option to purchase securities that, upon settlement of the forward contract or exercise of the purchased option, would be accounted for under the equity method of accounting or the fair value option in accordance with Topic 825, Financial Instruments. These amendments improve current GAAP by reducing diversity in practice and increasing comparability of the accounting for these interactions. The amendments in this update are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The adoption of this standard will not have a material impact on our disclosures or consolidated financial statements. 17 8. INCOME TAXES We recognize deferred tax assets and liabilities for the estimated future tax effects of events that have been recognized in our financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance is established, when necessary, to reduce deferred tax assets to the amount expected to be realized. We have provided a full valuation allowance against our deferred tax asset due to our historical pre-tax losses and the uncertainty regarding the realizability of these deferred tax assets. We have substantial net operating loss carryforwards for Federal and California income tax returns. These net operating loss carryforwards could be subject to limitations under Internal Revenue Code section 382. We have no unrecognized income tax benefits as of July 31, 2021 and October 31, 2020 and we account for interest and penalties related to income tax matters, if any, in general and administrative expenses. 9. LEASES We lease approximately 2,000 square feet of office space at 3150 Almaden Expressway, San Jose, California (our principal executive offices) from an unrelated party pursuant to an operating lease that expires September 30, 2021 . Our base rent is approximately $ 5,000 per month and the lease provides for annual increases of approximately 3 % and an escalation clause for increases in certain operating costs. Rent expense was approximately $ 16,000 and $ 16,000 , respectively, for the three months ended July 31, 2021 and 2020, and approximately $ 48,000 and $ 48,000 , respectively, for the nine months ended July 31, 2021 and 2020. On November 1, 2019, the Company adopted ASC 842, which increases transparency and comparability by recognizing a lessee’s rights and obligations resulting from leases by recording them on the balance sheet as lease assets and lease liabilities. The new guidance requires the recognition of the right-of-use (“ROU”) assets and related operating lease liabilities on the balance sheet. The Company adopted the new guidance using the modified retrospective approach on November 1, 2019. For operating leases, the lease liability is initially and subsequently measured at the present value of the unpaid lease payments. The remaining 2 -month lease term as of July 31, 2021 for the Company’s lease includes the noncancelable period of the lease. The lease does not contain a Company option to extend the lease or an option to extend the lease controlled by the lessor. All ROU assets are reviewed for impairment. 18 Balance sheet information related to the Company’s lease is presented below: SCHEDULE OF OPERATING LEASE Balance Sheet Location July 31, 2021 October 31, 2020 Operating Lease: Right-of-use asset Operating lease right-of-use asset $ 10,411 $ 54,340 Right-of-use liability, current Operating lease liability 10,567 55,198 As of July 31, 2021, the annual minimum lease payments of our operating lease liabilities were as follows: SCHEDULE OF MINIMUM LEASE PAYMENTS Operating Leases 2021 future minimum payments, undiscounted $ 10,752 Less: Imputed interest ( 185 ) Present value of future minimum lease payments $ 10,567 In August 2021 the lease was extended until September 30, 2024 under substantially the same terms as the existing lease. 10. COMMITMENTS AND CONTINGENCES Litigation Matters We are not involved in any litigation or other legal proceedings and management is not aware of any pending litigation or legal proceeding against us that would have a material adverse effect upon our results of operations or financial condition. Impact of Coronavirus Pandemic On March 10, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. The virus and actions taken to mitigate its spread have had and are expected to continue to have a broad adverse impact on the economies and financial markets of many countries, including the geographical areas in which the Company operates and conducts its business, and which the Company’s partners operate and conduct their business. We are currently following the recommendations of local health authorities to minimize exposure risk for our team members and visitors. However, while the outlook is improving, and there has been a loosening of restrictions in many of the areas in which we and our partners operate and conduct our business, the scale and scope of this pandemic is unknown, and the duration of the business disruption and related financial impact cannot be reasonably estimated at this time. While we have implemented specific business continuity plans to reduce the potential impact of COVID-19, there is no guarantee that our continuity plans will be successful. We have experienced certain disruptions to our business such as temporary closure of our offices and similar disruptions have occurred for our partners. Specifically, the outbreak has caused temporary shutdowns of the laboratories and other service providers that we rely on to develop our programs, and those laboratories and service providers that have been operating or that have begun operating recently have been doing so with more limited capacity due to social distancing requirements. As a result, our progress has been slowed and there is no assurance that we will be able to meet our previously announced timelines regarding the advancement of our programs. The extent to which COVID-19 or any other health epidemic may impact our results will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others. Accordingly, COVID-19 could have a material adverse effect on our business, results of operations, financial condition and prospects. 19 11. SEGMENT INFORMATION We follow the accounting guidance of ASC 280 “Segment Reporting” (“ASC 280”). Reportable operating segments are determined based on the management approach. The management approach, as defined by ASC 280, is based on the way that the chief operating decision-maker organizes the segments within an enterprise for making operating decisions and assessing performance. While our results of operations are primarily reviewed on a consolidated basis, the chief operating decision-maker manages the enterprise in five reportable segments, each with different operating and potential revenue generating characteristics: (i) CAR-T Therapeutics, (ii) Cancer Vaccines, (iii) Anti-Viral Therapeutics, (iv) Cancer Diagnostics and (v) Patent Licensing activities. The following represents selected financial information for our segments for the three and nine months ended July 31, 2021 and 2020 and as of July 31, 2021 and October 31, 2020: SCHEDULE OF SEGMENT INFORMATION 2021 2020 2021 2020 For the Three Months Ended July 31, For the Nine Months Ended July 31, 2021 2020 2021 2020 Net Income/(Loss): CAR-T Therapeutics $ ( 1,618,860 ) $ ( 417,502 ) $ ( 4,025,354 ) $ ( 1,542,865 ) Cancer Vaccines ( 1,464,323 ) ( 178,738 ) ( 3,033,026 ) ( 544,605 ) Anti-Viral Therapeutics ( 1,262,260 ) ( 281,098 ) ( 2,052,821 ) ( 590,602 ) Cancer Diagnostics ( 38,198 ) ( 1,693,304 ) ( 60,569 ) ( 5,162,977 ) Patent Licensing ( 3,969 ) ( 6,145 ) 114,894 ( 10,303 ) Total $ ( 4,387,610 ) $ ( 2,576,787 ) $ ( 9,056,876 ) $ ( 7,851,352 ) Net Income/(Loss) $ ( 4,387,610 ) $ ( 2,576,787 ) $ ( 9,056,876 ) $ ( 7,851,352 ) Total operating costs and expenses $ 4,388,236 $ 2,435,969 $ 9,571,149 $ 7,735,975 Less non-cash share-based compensation ( 3,187,326 ) ( 1,041,799 ) ( 5,224,697 ) ( 3,173,219 ) Operating costs and expenses excluding non-cash share-based compensation $ 1,200,910 $ 1,394,170 $ 4,346,452 $ 4,562,756 Operating costs and expenses excluding non-cash share-based compensation: CAR-T Therapeutics $ 411,313 $ 189,589 $ 1,903,707 $ 759,752 Cancer Vaccines 348,535 72,968 1,185,060 238,297 Anti-Viral Therapeutics 418,285 155,224 826,716 376,242 Cancer Diagnostics 20,645 971,698 37,368 3,180,511 Patent Licensing 2,132 4,691 393,601 7,954 Total $ 1,200,910 $ 1,394,170 4,346,452 $ 4,562,756 Operating costs and expenses excluding non-cash share-based compensation $ 1,200,910 $ 1,394,170 4,346,452 $ 4,562,756 July 31, 2021 October 31, 2020 Total assets: CAR-T Therapeutics $ 12,709,167 $ 2,988,124 Cancer Vaccines 10,706,026 946,923 Anti-Viral Therapeutics 12,849,445 2,464,361 Cancer Diagnostics 682,943 2,869,529 Patent Licensing 114,810 184,027 Total $ 37,062,391 $ 9,452,964 Total assets $ 37,062,391 $ 9,452,964 Operating costs and expenses excluding non-cash share-based compensation expense is the measurement the chief operating decision-maker uses in managing the enterprise. 20